Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer

被引:34
|
作者
Wang, Keshan [1 ]
Ruan, Hailong [1 ]
Xu, Tianbo [1 ]
Liu, Lei [1 ]
Liu, Di [1 ]
Yang, Hongmei [2 ]
Zhang, Xiaoping [1 ]
Chen, Ke [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Dept Urol, Tongji Med Coll, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Sch Basic Med, Dept Pathogen Biol, Wuhan 430030, Hubei, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2018年 / 11卷
基金
中国国家自然科学基金;
关键词
CRPC; androgen receptor; tumor immunity; mechanism; therapy; ANDROGEN RECEPTOR ACTIVATION; DOUBLE-BLIND; ENZALUTAMIDE MDV3100; ABIRATERONE ACETATE; CHEMOKINE RECEPTOR; CELL-PROLIFERATION; SURVIVAL ANALYSIS; PHASE-III; KAPPA-B; EXPRESSION;
D O I
10.2147/OTT.S159777
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: Although there have been great advances in mechanisms and therapeutic methods of prostate cancer, the mortality rate of prostate cancer remains high. The castration-resistant prostate cancer (CRPC), which develops from hormone-sensitive prostate cancer, foreshadows a more dismal outcome. Concomitant with the researches in the mechanism of CRPC and therapy for CRPC, more and more landmark progress has been made in recent years. Methods: A number of clinical and experimental studies were reviewed to indicate the novel advancement in the progressive mechanism and therapy of CRPC. Results: The androgen receptor (AR) is still a vital driver in the progression of CRPC, while other multiple mechanisms also contribute to this progression, such as tumor immunity, cancer stem cells, epithelial-mesenchymal transition and DNA repair disorder. In terms of the therapeutic methods of CRPC, chemotherapy with drugs, such as docetaxel, has been the first-line therapy for CRPC for many years. Besides, newer agents, which target some of the above mechanisms, show additional overall survival benefits for CRPC patients. These therapies include drugs targeting the androgen axis pathway (androgen synthesis, androgen receptor splice variants, coactivators of AR and so on), PI3K-AKT pathway, WNT pathway, DNA repair, rearrangement of ETS gene, novel chemotherapy and immunotherapy, bone metastasis therapy and so on. Understanding these novel findings on the mechanisms of CRPC and the latest potential CRPC therapies will direct us for further exploration of CRPC. Conclusion: Through comprehensive consideration, the predominant mechanism of CRPC might be the AR signal axis concomitant with tumor microenvironment, stress, immunity, tumor microenvironment and so on. For CRPC therapy, targeting the AR axis pathway and chemotherapy are the first-line treatments at present. However, with the advancements in CRPC therapy made by the researchers, other novel potential methods will occupy more and more important position in the treatment of CRPC, especially the therapies targeting the tumor microenviroment, tumor immunity and DNA repair and so on.
引用
收藏
页码:3167 / 3178
页数:12
相关论文
共 50 条
  • [1] Recent advances in the therapy of castration-resistant prostate cancer: The price of progress
    Vasani, Dhwanishiva
    Josephson, David Y.
    Carmichael, Courtney
    Sartor, Oliver
    Pal, Sumanta Kumar
    MATURITAS, 2011, 70 (02) : 194 - 196
  • [2] Management of Metastatic Castration-Resistant Prostate Cancer Recent Advances
    Mukherji, Deborah
    Eichholz, Andrew
    De Bono, Johann S.
    DRUGS, 2012, 72 (08) : 1011 - 1028
  • [3] Advances in metastatic castration-resistant prostate cancer
    Kentepozidis, Nikolaos
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S108 - S108
  • [4] Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction
    John Esther
    Benjamin L. Maughan
    Neysi Anderson
    Neeraj Agarwal
    Andrew W. Hahn
    Current Treatment Options in Oncology, 2019, 20
  • [5] Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
    Chen, Qiao-Hong
    Munoz, Erick
    Ashong, Dennis
    CANCERS, 2024, 16 (03)
  • [6] Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction
    Esther, John
    Maughan, Benjamin L.
    Anderson, Neysi
    Agarwal, Neeraj
    Hahn, Andrew W.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (02)
  • [7] Pathophysiology and therapy of castration-resistant prostate cancer
    Merseburger, A. S.
    Kuczyk, M. A.
    Wolff, J. M.
    UROLOGE, 2013, 52 (02): : 219 - 225
  • [8] Satraplatin for the therapy of castration-resistant prostate cancer
    Sonpavde, Guru
    Sternberg, Cora N.
    FUTURE ONCOLOGY, 2009, 5 (07) : 931 - 940
  • [9] An update on TroVax® for the treatment of progressive castration-resistant prostate cancer
    Abern, Michael
    Kaufman, Howard L.
    Latchamsetty, Kalyan
    ONCOTARGETS AND THERAPY, 2011, 4 : 33 - 41
  • [10] A Novel Mechanism to Drive Castration-Resistant Prostate Cancer
    Kaochar, Salma
    Mitsiades, Nicholas
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2018, 29 (06): : 366 - 368